The Wall Street Transcript
The Wall Street Transcript - In-Depth Interviews for Investors
Healthcare >> CEO Interviews >> July 29, 2015

Interview with the CEO: Tobira Therapeutics, Inc. (TBRA)

Laurent Fischer
Laurent Fischer is the CEO of Tobira Therapeutics, Inc. He joined the board of directors in April 2009 and became Chief Executive Officer in March 2014. Dr. Fischer brings over 20 years of drug development and commercialization experience in the biopharmaceutical industry. Prior to joining Tobira full time, he was Chairman and Chief Executive Officer of Jennerex, a private, clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class, breakthrough, targeted oncolytic immunotherapy products for cancer that was sold for up to $150 million. Prior to Jennerex, he was Co-Founder, President and CEO of Ocera Therapeutics, where he licensed and developed OCR-002 the first ammonia scavenger for the treatment of complications of liver disease and oversaw the approval of Zysa, the first treatment approved for irritable bowel syndrome in Europe. Dr. Fischer has co-founded and managed four health care companies and held senior management positions at DuPont Merck, DuPont Pharmaceuticals and Hoffmann-La Roche in liver disease, virology and oncology. Dr. Fischer was responsible for the global launch of Sustiva, the first once-daily anti-HIV therapy, now part of the fixed dose combination therapy Atripla, and he was involved in the launch of Invirase, the first protease inhibitor, in the United States. Dr. Fischer received his undergraduate degree from the University of Geneva and his medical degree from the Geneva Medical School, Switzerland. Profile
TWST: Could you provide a brief overview of the company?

Dr. Fischer: Tobira has been a public company since May 4 of this year. Our focus is on developing drugs for advanced liver

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
Walmart Inc.
International Business Machines Corporation
Citigroup Inc.
Exxon Mobil Corporation
Bank of America Corporation
Dell Inc.
Verizon Communications Inc.
Alphabet Inc

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS
Interview with the CEO: Pasithea Therapeutics Corp. (NASDAQ:KTTA)
Interview with the CEO: BetterLife Pharma Inc. (OTCMKTS:BETRF)
Interview with the CEO: Cansortium Inc. (OTCMKTS:CNTMF)
SECTOR ROUNDTABLES
Natural Gas Weighs Heavy On E&P Near-Term Prospects
Roundtable Forum:optimism Despite Uncertainty In For-profit Education
Roundtable Forum:a Shift In Focus To Natural Gas From Oil
MONEY MANAGER INTERVIEWS
Profitability Strategy Pays Off for Bank IT Company Q2 Holdings
Three Mid-Cap Names Using Their Balance Sheets to Create Value
Look Beyond Traditional Emerging Markets for More Diversification, Less Risk
ANALYST INTERVIEWS
Five Companies Dominate in Psychedelics-Based Drug Development
Cidara’s Long-Acting Antiviral Drug Could Be a Game Changer
Spotting Potential in the High-Risk, High Reward Neuroscience Space
Since 1963
© The Wall Street Transcript 2016, 2024
Terms and Conditions
Privacy Policy